Related references
Note: Only part of the references are listed.Neuroinflammation as a Common Feature of Neurodegenerative Disorders
Leonardo Guzman-Martinez et al.
FRONTIERS IN PHARMACOLOGY (2019)
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Fabio A. Zucca et al.
PROGRESS IN NEUROBIOLOGY (2017)
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas et al.
CNS DRUGS (2016)
Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity
Tiago Silva et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Indanones As High-Potency Reversible Inhibitors of Monoamine Oxidase
Samantha Mostert et al.
CHEMMEDCHEM (2015)
Medicinal Chemistry of Catechol O-Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility
Laszlo E. Kiss et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems
Lars Brichta et al.
TRENDS IN NEUROSCIENCES (2013)
Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-methyltransferase Inhibitors and Substrates
Ronald G. Robinson et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Pharmacokinetics of levodopa
Manuela Contin et al.
JOURNAL OF NEUROLOGY (2010)
Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives
Afshin Fassihi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2009)
Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase
Kirk E. Hevener et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2009)
Crystal structures of human 108V and 108M catechol O-methyltransferase
K. Rutherford et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Protection against Parkinson's disease progression: Clinical experience
Peter A. LeWittt et al.
NEUROTHERAPEUTICS (2008)
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease
Andrew J. Lees
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Improved assay for catechol-O-methyltransferase activity utilizing norepinephrine as an enzymatic substrate and reversed-phase high-performance liquid chromatography with fluorescence detection
N Aoyama et al.
JOURNAL OF CHROMATOGRAPHY A (2005)
Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease
S Kaakkola
DRUGS (2000)
Share Paper
